Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 1
Opinion
Video
Overview of BCG-Unresponsive NMIBC
Author(s):
Key Takeaways
- BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy.
- This condition requires alternative therapeutic strategies or radical cystectomy due to the failure of BCG treatment.
Katie S. Murray, DO, provides an overview of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), defining it as a form of bladder cancer that does not respond to BCG therapy and explaining how it differs from BCG-responsive NMIBC in terms of treatment outcomes and disease progression.
Video Player is loading.
- Would you please start by giving a brief overview of BCG-unresponsive NMIBC?
- What defines this condition?
- How does it differ from NMIBC that responds to BCG treatment?
Related Videos
Future Directions of BCG-Unresponsive NMIBC Management
Adoption of New Treatments for BCG-Unresponsive NMIBC
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Discussing Treatment Options for BCG-Unresponsive NMIBC
Related Content
